Skip to search formSkip to main contentSkip to account menu

Cytokine Release Syndrome

A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension… 
National Institutes of Health

Related topics

Related topics

1 relation
Immune System Diseases

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release… 
Highly Cited
2020
Highly Cited
2020
The association of interleukin‐6 value, interleukin inhibitors, and outcomes of patients with COVID‐19 in New York City
Since cytokine release syndrome with elevation of interleukin‐6 (IL‐6) is considered to be associated with severe cases of… 
2020
2020
Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1.
Interleukin 1 (IL-1) is a potential target of therapy in COVID-19 during the severe respiratory-inflammatory phase ("cytokine… 
2019
2019
A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas
2017
2017
Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.
3020Background: CD19 CAR-T cells have produced impressive responses in CD19+ ALL, NHL and CLL. Detailed understanding of the… 
2014
2014
Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL
CTL019 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) consisting of an external anti… 
Review
2010
Review
2010
Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.
Infusion reactions and cytokine release syndrome (CRS) are an emerging issue in drug development and are of particular importance… 
1999
1999
A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.
BACKGROUND An anti-CD3 antibody that reduces cytokine release syndrome (CRS) while maintaining immunosuppression would be a major… 
1999
1999
Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation.
Although life-long administration of a multi-drug regi- with high aYnity ( Kd=10’11 M ). The interaction of men of aspecific… 
1996
1996
Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
The use of OKT3 as an immunosuppressive agent is accompanied by increased cytokine production and constellation of side effects… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)